Cost effectiveness of implantable cardioverter defibrillators for 1.5 primary prevention of sudden cardiac arrest in China: an analysis from the Improve SCA study

References

• Shen C, Ge J. Epidemic of cardiovascular disease in China: current perspective and prospects for the future. Circulation. 2018;138(4):342–344. doi: 10.1161/CIRCULATIONAHA.118.033484.
   PubMed Web of Science ®Google Scholar
• Shengshou HU, Runlin GAO, Lisheng LIU, et al. Summary of the 2018 report on cardiovascular diseases in China. Chinese Circ J. 2019;34(03):209–220.
   Google Scholar
• Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–2867. doi: 10.1093/eurheartj/ehv316.
   PubMed Web of Science ®Google Scholar
• Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. [published correction appears in Circulation. 2009 Aug 4; 120(5):e34-5]. Circulation. 2008;117(21):e350–e408.
   PubMed Web of Science ®Google Scholar
• Zhang S, Singh B, Rodriguez DA, et al. Improve the prevention of sudden cardiac arrest in emerging countries: the improve SCA clinical study design. Europace. 2015;17(11):1720–1726. doi: 10.1093/europace/euv103.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ching CK, Huang D, et al. Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: improve SCA clinical trial. Heart Rhythm. 2020;17(3):468–475. doi: 10.1016/j.hrthm.2019.09.023.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11(6):716–726. doi: 10.1093/europace/eup068.
   PubMed Web of Science ®Google Scholar
• Wang LT, Peng LB, Peng Y, et al. Comparative analysis between 2020 version and 2011 version on China guidelines for pharmacoeconomic evaluation. China J Pharm Econ. 2021;16(03):5–8 + 15.
   Google Scholar
• Guidelines for rational use of heart failure medications. 2nd ed. Chinese J Front Med Sci. 2019;11(07):1–78.
   Google Scholar
• Liang Y, Zhang S, Zhang Z, et al. Implantable cardioverter defibrillators for sudden cardiac death prevention in China: a regional analysis from the improve SCA clinical trial. Int J Heart Rhythm. 2020;5(1):1. doi: 10.4103/IJHR.IJHR_7_20.
   Google Scholar
• Hammill SC, Kremers MS, Stevenson LW, et al. Review of the registry’s fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm. 2010;7(9):1340–1345. doi: 10.1016/j.hrthm.2010.07.015.
   PubMed Web of Science ®Google Scholar
• Ghani A, Delnoy PP, Ramdat Misier AR, et al. Incidence of lead dislodgement, malfunction and perforation during the first year following device implantation. Neth Heart J. 2014;22(6):286–291. doi: 10.1007/s12471-014-0556-6.
   PubMed Web of Science ®Google Scholar
• Providência R, Kramer DB, Pimenta D, et al. Transvenous implantable cardioverter-defibrillator (ICD) lead performance: a meta-analysis of observational studies. J Am Heart Assoc. 2015;4(11):e002418.
   PubMed Web of Science ®Google Scholar
• Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation. 2010;122(16):1553–1561. doi: 10.1161/CIRCULATIONAHA.110.976076.
   PubMed Web of Science ®Google Scholar
• Gasparini M, Proclemer A, Klersy C, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013;309(18):1903–1911. [published correction appears in JAMA. 2013 Jun 26;309(24):2552]. doi: 10.1001/jama.2013.4598.
   PubMed Web of Science ®Google Scholar
• Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: pain Free SST trial primary results. Heart Rhythm. 2015;12(5):926–936. doi: 10.1016/j.hrthm.2015.01.017.
   PubMed Web of Science ®Google Scholar
• Saeed M, Hanna I, Robotis D, et al. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol. 2014;25(1):52–59. doi: 10.1111/jce.12273.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367(24):2275–2283. doi: 10.1056/NEJMoa1211107.
   PubMed Web of Science ®Google Scholar
• Eby EL, Bengtson LGS, Johnson MP, et al. Economic impact of cardiac implantable electronic device infections: cost analysis at one year in a large U.S. health insurer. J Med Econ. 2020;23(7):698–705. doi: 10.1080/13696998.2020.1751649.
   PubMed Web of Science ®Google Scholar
• Hussein AA, Baghdy Y, Wazni OM, et al. Microbiology of cardiac implantable electronic device infections. JACC Clin Electrophysiol. 2016;2(4):498–505. doi: 10.1016/j.jacep.2016.01.019.
   PubMedGoogle Scholar
• China Statistical Yearbook. 2021. http://www.stats.gov.cn/sj/ndsj/2021/indexch.htm.
   Google Scholar
• Li H, Natale A, Zhu W, et al. Causes and consequences of discontinuation of the implantable cardioverter-defibrillator therapy in non-terminally ill patients. Am J Cardiol. 1998;81(10):1203–1205. doi: 10.1016/s0002-9149(98)00090-3.
   PubMed Web of Science ®Google Scholar
• Holbrook R, Higuera L, Wherry K, et al. Implantable cardioverter defibrillator therapy is cost effective for primary prevention patients in Taiwan: an analysis from the improve SCA trial. PLoS One. 2020;15(11):e0241697. doi: 10.1371/journal.pone.0241697.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471–1480. doi: 10.1056/NEJMsa051989.
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics of China. Statistical communiqué of the People's Republic of China on the 2022 National Economic and Social Development. 2022. http://www.stats.gov.cn/sj/zxfb/202302/t20230228_1919011.html.
   Google Scholar
• Higuera L, Holbrook R, Wherry K, et al. Comparison of cost-effectiveness of implantable cardioverter defibrillator therapy in patients for primary prevention in Latin America: an analysis using the improve SCA study. J Med Econ. 2021;24(1):173–180. doi: 10.1080/13696998.2021.1877451.
   PubMed Web of Science ®Google Scholar
• Younis A, Wilkoff BL. Implantable cardioverter-defibrillator for primary prevention in Asia. JACC Asia. 2023;3(3):321–334. doi: 10.1016/j.jacasi.2022.11.014.
   PubMedGoogle Scholar
• Patel NJ, Edla S, Deshmukh A, et al. Gender, racial, and health insurance differences in the trend of implantable cardioverter-defibrillator (ICD) utilization: a United States experience over the last decade. Clin Cardiol. 2016;39(2):63–71. doi: 10.1002/clc.22496.
   PubMed Web of Science ®Google Scholar
• Singh B, Zhang S, Ching CK, et al. Improving the utilization of implantable cardioverter defibrillators for sudden cardiac arrest prevention (improve SCA) in developing countries: clinical characteristics and reasons for implantation refusal. Pacing Clin Electrophysiol. 2018;41(12):1619–1626. doi: 10.1111/pace.13526.
   PubMed Web of Science ®Google Scholar
• Wherry K, Holbrook R, Higuera L, et al. Cost-effectiveness analysis of implantable cardioverter defibrillator therapy for primary prevention patients with additional risk factors in Brazil. Int J Cardiovasc Sci. 2021;34(6):692–701.
   Google Scholar